Monotherapy Study of MP-513 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in
patients with type 2 Diabetes for 12 weeks administration.